Skip to main content
[Preprint]. 2022 Nov 28:2022.11.27.518117. [Version 1] doi: 10.1101/2022.11.27.518117

Figure 4. Protection against SARS-CoV-2 BA.5 infection after mRNA-1273 vaccination of wild-type and FcγR-deficient C57BL/6 mice.

Figure 4.

(a) Scheme of immunization, serum sampling, virus challenge, and tissue harvest. (b-c) Anti-Wuhan-1 (b) and BA.4/5 (c) RBD IgG responses from serum of mice immunized with control or mRNA-1273 vaccines (n = 10–22, boxes illustrate geometric mean titers [GMT], dotted lines show LOD). (d-e) Neutralizing antibody responses against WA1/2020 N501Y/D614G (d) and BA.5 (e) from serum collected from wild-type, FcγR I KO, FcγR III KO, and FcγR I/III/IV KO mice 25 days after completion of a two-dose primary vaccination series with control (closed circles) or mRNA-1273 (open circles). (f-g) Nine-week-old male wild-type, FcγR I KO, FcγR III KO, and FcγR I/III/IV KO mice were immunized twice at four-week intervals with control or mRNA-1273 vaccine via intramuscular route. Four weeks after the primary vaccination series, mice were challenged via intranasal route with 104 FFU of BA.5. At 3 dpi, infectious virus in the nasal turbinates (f) and lungs (g) was determined by plaque assay (bars indicate median values; n = 8–10 mice per group, two experiments, dotted lines show LOD, one-way ANOVA with Dunnett’s test (ns, not significant, **P < 0.01, ***P < 0.0001, ****P < 0.0001).